advertisement
Yang Y 23
Showing records 1 to 23 | Display all abstracts from Yang Y106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Sheng B
Frontiers in public health 2022; 10: 971943
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Wang N
International immunopharmacology 2022; 112: 109242
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Huang S; Yang Y
European Journal of Dermatology 2022; 32: 589-596
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Yang Y
International immunopharmacology 2022; 112: 109242
106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Chen X
Frontiers in public health 2022; 10: 971943
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Liu Y
International immunopharmacology 2022; 112: 109242
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Ouyang Z
European Journal of Dermatology 2022; 32: 589-596
106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Li T
Frontiers in public health 2022; 10: 971943
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Guo X
European Journal of Dermatology 2022; 32: 589-596
106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Ma T
Frontiers in public health 2022; 10: 971943
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Huang L
International immunopharmacology 2022; 112: 109242
106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Yang Y
Frontiers in public health 2022; 10: 971943
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Gu M
International immunopharmacology 2022; 112: 109242
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Zhan Z
European Journal of Dermatology 2022; 32: 589-596
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Wu Y
International immunopharmacology 2022; 112: 109242
106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Bi L
Frontiers in public health 2022; 10: 971943
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Liu X
European Journal of Dermatology 2022; 32: 589-596
106374 An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Zhang X
Frontiers in public health 2022; 10: 971943
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Chen Z
European Journal of Dermatology 2022; 32: 589-596
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Xu L
International immunopharmacology 2022; 112: 109242
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Xu J
European Journal of Dermatology 2022; 32: 589-596
105856 Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury
Sun H; Guo W
International immunopharmacology 2022; 112: 109242
106568 The risk of glaucoma associated with phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata
Yu M
European Journal of Dermatology 2022; 32: 589-596
